Loading
Life sciences · Phase 2/3 Trial
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2/3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07920549). This is a study registration, not published results. Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 150 participants (ESTIMATED). Conditions: Limited Stage Small-Cell Lung Cancer. Interventions: RADIATION: Radiation Therapy; RADIATION: Hypofractionated Radiation Therapy; DRUG: Chemotherapy. Primary outcome measures: Progression-free survival , From randomization to disease progression or death, assessed for up to 60 months.. Brief summary: This study aims to determine whether an abbreviated course of thoracic radiotherapy, delivered in five fractions over one week between chemotherapy cycles, improves progression-free survival compared with standard radiotherapy delivered concurrently with chemotherapy in patients with newly diagnosed limited-stage small cell lung cancer (LS-SCLC).